{"contentid": 487945, "importid": NaN, "name": "Still no luck for GSK in fight against novel coronavirus", "introduction": "GlaxoSmithKline and Vir Biotechnology have stopped enrollment in the Phase III ACTIV trial testing VIR-7831 as a treatment for COVID-19.", "content": "<p><span style=\"font-weight: 400;\">GlaxoSmithKline (LSE: GSK) and Vir Biotechnology (Nasdaq: VIR) have stopped enrollment in the Phase III ACTIV trial testing VIR-7831 as a treatment for COVID-19.</span></p>\n<p><span style=\"font-weight: 400;\">The decision follows an update from trial monitors indicating that, while there were no reported safety signals, the magnitude of potential benefit was unclear.</span></p>\n<p><span style=\"font-weight: 400;\">Shares in San Francisco-based Vir tumbled over a quarter following the announcement, while GSK stock was unaffected.</span></p>\n<p><span style=\"font-weight: 400;\">GSK has had a run of bad luck targeting the novel coronavirus, with </span><a href=\"https://www.thepharmaletter.com/article/slower-progress-for-sanofi-and-gsk-s-coronavirus-vaccine\"><span style=\"font-weight: 400;\">delays to its vaccine program</span></a><span style=\"font-weight: 400;\"> followed more recently by </span><a href=\"https://www.thepharmaletter.com/article/gsk-amends-trial-after-otilimab-misses-endpoint-in-covid-19\"><span style=\"font-weight: 400;\">poor results</span></a><span style=\"font-weight: 400;\"> from a Phase II study of another antibody candidate, otilimab.&nbsp;</span></p>\n<h2><strong>Targeting COVID-19</strong></h2>\n<p><span style=\"font-weight: 400;\">Vir and GSK have been working together on VIR-7831, an investigational dual-action antibody, since mid-2020.</span></p>\n<p><span style=\"font-weight: 400;\">The firms believe it has the potential to neutralize the virus, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs.</span></p>\n<p><span style=\"font-weight: 400;\">As part of their work, the antibody was included in the National Institutes of Health&rsquo;s (NIH)-sponsored ACTIV trial, as well as the separate Phase III COMET-ICE trial in newly-diagnosed COVID-19 patients.</span></p>\n<p><span style=\"font-weight: 400;\">Enrollment in the ACTIV trial will be stopped while the companies discuss with the NIH &ldquo;appropriate ways to further assess the potential of VIR-7831 in the hospitalized population.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">GSK and Vir are still awaiting data from the COMET-ICE trial, which will give a clearer indication of whether the candidate has potential in this area.</span></p>\n<p><span style=\"font-weight: 400;\">Vir chief executive George Scangos said: &ldquo;While we are disappointed with the recommendation of the DSMB, we are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">&ldquo;In addition, we are eagerly anticipating the upcoming data from the Phase III COMET-ICE trial in newly-diagnosed COVID-19 patients at high risk of hospitalization,&rdquo; he added.</span></p>\n<p><span style=\"font-weight: 400;\">As well as in COMET-ICE, VIR-7831 is being evaluated in the outpatient setting in BLAZE-4, a Phase II study sponsored by Eli Lilly (NYSE: LLY) testing the biologic in combination with bamlanivimab.</span></p>", "date": "2021-03-04 13:03:00", "meta_title": NaN, "meta_keywords": "trial, Phase, VIR-, COVID-, ACTIV, potential, COMET-ICE, enrollment, stopped, testing, antibody, high, coronavirus, luck, patients, Biotechnology, treatmen", "meta_description": "GlaxoSmithKline and Vir Biotechnology have stopped enrollment in the Phase III ACTIV trial testing VIR-7831 as a treatment for COVID-19.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-04 13:02:52", "updated": "2021-03-04 13:48:27", "access": NaN, "url": "https://www.thepharmaletter.com/article/still-no-luck-for-gsk-in-fight-against-novel-coronavirus", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "glaxo_gsk_glaxosmithkline_big.jpg", "image2id": "glaxo_gsk_glaxosmithkline_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Infectious diseases", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "UK, USA", "company_tag": "GlaxoSmithKline, Vir Biotechnology", "drug_tag": "VIR-7831", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-04 13:03:00"}